Eltrombopag and Vorinostat
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Trial Timeline
Oct 1, 2012 → May 1, 2014
NCT ID
NCT01500538About Eltrombopag and Vorinostat
Eltrombopag and Vorinostat is a phase 2 stage product being developed by Merck for Follicular Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01500538. Target conditions include Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01500538 | Phase 2 | Terminated |
Competing Products
20 competing products in Follicular Lymphoma